Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis
Introduction Progressive pulmonary fibrosis (PPF) corresponds to any fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) that presents clinical, physiological and/or radiological evidence of disease progression similar to IPF. Matrix metalloproteinases (MMPs) have...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2024-12-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/10/6/00553-2024.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841537028428136448 |
|---|---|
| author | Márcia Araújo Marília Beltrão Oksana Sokhatska Natália Melo Patrícia Caetano Mota Helder Novais Bastos André Terras David Coelho Luís Delgado António Morais |
| author_facet | Márcia Araújo Marília Beltrão Oksana Sokhatska Natália Melo Patrícia Caetano Mota Helder Novais Bastos André Terras David Coelho Luís Delgado António Morais |
| author_sort | Márcia Araújo |
| collection | DOAJ |
| description | Introduction
Progressive pulmonary fibrosis (PPF) corresponds to any fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) that presents clinical, physiological and/or radiological evidence of disease progression similar to IPF. Matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of pulmonary fibrosis and are associated with disease progression and reduced survival in IPF and other fibrotic ILDs. This study aimed to investigate the role of serum levels of MMP-1 and MMP-7 in patients with fibrotic non-IPF ILD as possible biomarkers of patients at risk of developing PPF.
Methods
Newly diagnosed patients with fibrotic non-IPF ILD were included in this study. Serum levels of MMP-1 and MMP-7 were quantified at baseline and disease progression was monitored. PPF was defined according to the recent European Respiratory Society, American Thoracic Society, Japanese Respiratory Society and the Latin American Thoracic Society Clinical Practice Guidelines.
Results
79 patients with fibrotic non-IPF ILDs were included and classified as having PPF or non-PPF. Significantly higher levels of MMP-7, but not MMP-1, were detected in the PPF group (p=0.01). MMP-7 was independently associated with PPF (adjusted OR 1.263, 95% CI 1.029–1.551; p=0.026) after adjustment for sex, age and smoking history. A cut-off value of 3.53 ng·mL−1 for serum MMP-7 levels had a sensitivity of 61% and a specificity of 74% for predicting PPF in non-IPF ILDs.
Conclusions
In patients with fibrotic non-IPF ILDs, serum MMP-7 levels were significantly greater in the subgroup of patients meeting the PPF criteria at follow-up. This can be considered and further investigated as a possible biomarker to identify fibrotic ILD patients at risk of PPF. |
| format | Article |
| id | doaj-art-5f8361411863477f91a7b98843f41ed0 |
| institution | Kabale University |
| issn | 2312-0541 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj-art-5f8361411863477f91a7b98843f41ed02025-01-14T09:50:22ZengEuropean Respiratory SocietyERJ Open Research2312-05412024-12-0110610.1183/23120541.00553-202400553-2024Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosisMárcia Araújo0Marília Beltrão1Oksana Sokhatska2Natália Melo3Patrícia Caetano Mota4Helder Novais Bastos5André Terras6David Coelho7Luís Delgado8António Morais9 Department of Pulmonology, Hospital Pedro Hispano, Matosinhos, Portugal Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal Department of Pulmonology, Centro Hospitalar São João, Faculty of Medicine, University of Porto, Porto, Portugal Department of Pulmonology, Centro Hospitalar São João, Faculty of Medicine, University of Porto, Porto, Portugal Department of Pulmonology, Centro Hospitalar São João, Faculty of Medicine, University of Porto, Porto, Portugal Department of Pulmonology, Centro Hospitalar São João, Faculty of Medicine, University of Porto, Porto, Portugal Department of Pulmonology, Centro Hospitalar São João, Faculty of Medicine, University of Porto, Porto, Portugal Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal Department of Pulmonology, Centro Hospitalar São João, Faculty of Medicine, University of Porto, Porto, Portugal Introduction Progressive pulmonary fibrosis (PPF) corresponds to any fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) that presents clinical, physiological and/or radiological evidence of disease progression similar to IPF. Matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of pulmonary fibrosis and are associated with disease progression and reduced survival in IPF and other fibrotic ILDs. This study aimed to investigate the role of serum levels of MMP-1 and MMP-7 in patients with fibrotic non-IPF ILD as possible biomarkers of patients at risk of developing PPF. Methods Newly diagnosed patients with fibrotic non-IPF ILD were included in this study. Serum levels of MMP-1 and MMP-7 were quantified at baseline and disease progression was monitored. PPF was defined according to the recent European Respiratory Society, American Thoracic Society, Japanese Respiratory Society and the Latin American Thoracic Society Clinical Practice Guidelines. Results 79 patients with fibrotic non-IPF ILDs were included and classified as having PPF or non-PPF. Significantly higher levels of MMP-7, but not MMP-1, were detected in the PPF group (p=0.01). MMP-7 was independently associated with PPF (adjusted OR 1.263, 95% CI 1.029–1.551; p=0.026) after adjustment for sex, age and smoking history. A cut-off value of 3.53 ng·mL−1 for serum MMP-7 levels had a sensitivity of 61% and a specificity of 74% for predicting PPF in non-IPF ILDs. Conclusions In patients with fibrotic non-IPF ILDs, serum MMP-7 levels were significantly greater in the subgroup of patients meeting the PPF criteria at follow-up. This can be considered and further investigated as a possible biomarker to identify fibrotic ILD patients at risk of PPF.http://openres.ersjournals.com/content/10/6/00553-2024.full |
| spellingShingle | Márcia Araújo Marília Beltrão Oksana Sokhatska Natália Melo Patrícia Caetano Mota Helder Novais Bastos André Terras David Coelho Luís Delgado António Morais Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis ERJ Open Research |
| title | Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis |
| title_full | Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis |
| title_fullStr | Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis |
| title_full_unstemmed | Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis |
| title_short | Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis |
| title_sort | serum metalloproteinase 7 as a biomarker of progressive pulmonary fibrosis |
| url | http://openres.ersjournals.com/content/10/6/00553-2024.full |
| work_keys_str_mv | AT marciaaraujo serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis AT mariliabeltrao serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis AT oksanasokhatska serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis AT nataliamelo serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis AT patriciacaetanomota serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis AT heldernovaisbastos serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis AT andreterras serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis AT davidcoelho serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis AT luisdelgado serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis AT antoniomorais serummetalloproteinase7asabiomarkerofprogressivepulmonaryfibrosis |